Core Viewpoint - The stock of药捷安康-B (02617) experienced significant market interest, surging nearly 130% at one point during the day, ultimately closing up 77.09% at 192.5 HKD, with a total trading volume of 2.613 billion HKD and a turnover rate of approximately 4.74% [1] Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidate products and several preclinical candidates in its pipeline [1] Key Product Highlights - The core product,替恩戈替尼 (TT-00420), has garnered significant market attention due to multiple recent positive developments [1] - On September 10,替恩戈替尼 received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial in treating hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer [1] - The product is also involved in an open-label, multicenter Phase II clinical study for advanced hepatocellular carcinoma (HCC) in combination with 康方生物's 开坦尼/依达方, with the first patient recently dosed [1] - Additionally,替恩戈替尼 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer [1]

Core Viewpoint - The pharmaceutical sector is experiencing a rebound, with significant stock price increases for several companies following regulatory support for innovative drug clinical trial approvals [1] Group 1: Stock Performance - Several pharmaceutical stocks have seen notable gains, including: - Hutchison China MediTech (00013) up 11.04% to HKD 27.96 - Innovent Biologics (09969) up 10.76% to HKD 18.63 - Zai Lab (09688) up 7.84% to HKD 26.14 - Lepu Biopharma-B (02157) up 7.3% to HKD 8.53 - CanSino Biologics (09926) up 6.5% to HKD 136 [1] Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) has proposed to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [1] - This initiative supports key national R&D projects and encourages global early-stage synchronized development and international multi-center clinical trials [1] Group 3: Market Sentiment and Challenges - There are concerns regarding potential restrictions on Chinese innovative drugs in the U.S. market, but many pharmaceutical companies believe these rumors will not significantly impact the prospects for Chinese drugs abroad [1] - HSBC notes that the short-term emotional impact of these rumors may be greater than the actual damage, as prohibiting patent transactions is technically challenging [1] - Global pharmaceutical companies are facing a "patent cliff" risk and are in need of high-quality Chinese assets to strengthen their product pipelines, leading to lobbying against such administrative orders [1]

Core Viewpoint - Pharmaceutical stocks experienced a rebound today, with significant gains observed in several companies following regulatory news from the National Medical Products Administration (NMPA) regarding the optimization of clinical trial review and approval processes for innovative drugs [1] Group 1: Stock Performance - Hutchison China MediTech (00013) rose by 11.04%, trading at HKD 27.96 [1] - Innovent Biologics (09969) increased by 10.76%, trading at HKD 18.63 [1] - Zai Lab (09688) saw a rise of 7.84%, trading at HKD 26.14 [1] - Lepu Biopharma-B (02157) gained 7.3%, trading at HKD 8.53 [1] - CanSino Biologics (09926) increased by 6.5%, trading at HKD 136 [1] Group 2: Regulatory Developments - The NMPA announced a plan to further optimize the review and approval process for clinical trials of innovative drugs, aiming to complete reviews within 30 working days for eligible applications [1] - This initiative supports key national R&D projects and encourages global early-stage synchronized development and international multi-center clinical trials [1] Group 3: Market Sentiment and Risks - Recent negative rumors regarding potential restrictions on Chinese innovative drugs entering the U.S. market have been noted, but several pharmaceutical companies believe these rumors do not currently impact the expectations for Chinese innovative drugs abroad [1] - HSBC indicated that the short-term emotional impact of these rumors may be greater than the actual damage, as prohibiting patent transactions is technically challenging [1] - Global pharmaceutical companies are facing a "patent cliff" risk and are in need of high-quality Chinese assets to strengthen their product pipelines, leading to lobbying against such administrative orders [1]

Core Viewpoint - The stock of ZhiJie AnKang-B (02617) has surged nearly 88%, reaching a high of 204.6 HKD, representing an increase of over 1455% from its IPO price of 13.15 HKD, driven by its inclusion in the Hong Kong Stock Connect list and positive developments regarding its core product, Tiengertinib [1][1][1] Company Developments - ZhiJie AnKang's Tiengertinib is the world's first and only FGFR inhibitor to enter the registration clinical stage for treating patients with recurrent or refractory cholangiocarcinoma [1][1] - The company has received multiple positive updates for Tiengertinib, including the approval for a Phase II clinical trial in China for treating HR+ and HER2- recurrent or metastatic breast cancer, which was granted clinical implied permission on September 10 [1][1] - Tiengertinib is also involved in an open-label, multicenter Phase II clinical study for advanced hepatocellular carcinoma (HCC) in combination with other therapies, with the first patient recently dosed [1][1] - The drug has received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1][1]

Group 1 - The core index of the Hong Kong Stock Connect Innovative Drug ETF (520880) has been timely adjusted, leading to significant price increases in several newly added constituent stocks [1][3] - The stock of Yaojie Ankang-B surged over 80% on September 12, reaching a new high of over 200 HKD, with its price doubling in three days [1][2] - The ETF now exclusively tracks innovative drug development companies, reflecting the trends in the innovative drug industry [3][4] Group 2 - Yaojie Ankang-B's core product, Tinengotinib, received approval for a Phase II clinical trial for breast cancer on September 10 [2][3] - The ETF has seen increased capital inflow since its adjustment to focus solely on innovative drug companies, with significant net subscriptions occurring [4][6] - China's share of global new drug research has surpassed 20%, positioning it as the second-largest in the world, with several domestic innovative drugs receiving approval [6]

Market Performance - The Hang Seng Index rose by 1.53% at midday on the 12th [2] - The Hang Seng Tech Index increased by 2.18% [2] - The Hong Kong Stock Connect ETF (159318) gained 0.77% [2] - The Hong Kong Tech ETF (159751) saw an increase of 0.94% [2] Sector Performance - The metals and mining sector, along with the machinery manufacturing sector, showed strong gains [2] - The diversified REITs and biotechnology sectors experienced the largest declines [2] Individual Stock Movements - Baidu Group-SW surged by 8.54% [2] - China Hongqiao increased by 6.06% [2] - Alibaba-WR rose by 6.03% and Alibaba-W by 5.93% [2] - China Aluminum gained 5.92% [2] - Luoyang Molybdenum rose by 5.28% [2] - Kangfang Biotech increased by 4.38% [2] - Yimeng Biotech-B fell by 5.18% [2] - Hongteng Precision Technology dropped by 5.47% [2] - Yaojie Ankang-B surged over 55% [2] - Evergrande Property increased by 30.43% [2]

Group 1 - Evergrande Property (06666) resumed trading and rose over 28% as Evergrande and liquidators plan to sell shares, with potential transactions in preliminary stages [1] - Alibaba-W (09988) increased by over 5% and Baidu Group-W (09888) rose over 8% as both companies began using internally designed chips to train their AI models, replacing some NVIDIA chips [1] - China Merchants Energy (01138) saw a rise of over 5% after announcing plans to issue A-shares to raise no more than 8 billion yuan for fleet upgrades, with increased oil production expected to boost shipping demand [1] - Kangfang Biologics (09926) increased by over 4% after presenting excellent clinical data for its drug at WCLC, highlighting its global market value [1] - NIO-SW (09866) rose over 3% as it plans to publicly issue $1 billion in shares, with Goldman Sachs expecting the funds to support the company's product strategy [1] - WanGuo Data-SW (09698) surged over 15% as AI drives data center demand, with the company fully engaging in partnerships with cloud service providers [1] - Jiajian Ankang-B (02617) rose over 32%, with its market capitalization exceeding 50 billion HKD after receiving approval for a Phase II trial of its drug [1] Group 2 - Meitu (01357) increased by over 6% after announcing a partnership with Alibaba's Tongyi Laboratory to enhance its products with advanced AI models [2] - Robotics concept stocks mostly rose, with UBTECH (09880) up over 3%, ShouCheng Holdings (00697) up over 3%, Yuejiang (02432) up over 4%, and Jizhi Jia-W (02590) up over 6%, as domestic and international catalysts for humanoid robot commercialization are expected [2] - Bilibili-W (09626) rose over 2% as it revealed its new strategy card game "Three Kingdoms: Hundred Generals Card," with institutions optimistic about the company's growth potential with AI integration [2] Group 3 - Alibaba (BABA.US) rose 8.00% after the launch of the "Gaode Street Ranking," which attracted over 40 million users on its first day, becoming the largest food ranking in China [3] - XPeng Motors (XPEV.US) increased by 2.39% after receiving a special flight permit for its "land aircraft" (X3-F) in the UAE [3] - Trip.com (TCOM.US) rose 3.21% after forming a five-year strategic partnership with Cityline, marking its first collaboration with a major ticket supplier in Hong Kong and Macau [3] - NIO (NIO.US) increased by 6.21% after completing a $1 billion equity issuance, marking its second public financing plan this year [3] - Kingsoft Cloud (KC.US) rose 5.60% as Citigroup raised its target price to $20, citing strong AI-related demand from Xiaomi [3] - NetEase (NTES.US) continued to rise by 2.98%, reaching a historical high after launching its first sci-fi shooting mobile game based on the "Destiny" IP [3] Group 4 - Adobe (ADBE.US) rose 0.11% after launching its first AI agent product suite to help customers streamline workflows across various applications [4] - Hesai (HSAI.US) increased by 0.90% as sources reported its Hong Kong IPO priced at HKD 212.8 per share, raising at least HKD 3.62 billion with oversubscription nearly 120 times [4] - Tesla (TSLA.US) rose 6.04% as the Model Y L is set to launch in the domestic market on September 19, with orders extending to November [4] - Online real estate platform Opendoor (OPEN.US) surged 79.52% after appointing Kaz Nejatian as the new CEO, with co-founder Keith Rabois returning to the board [4]

Core Viewpoint - Company maintains a "buy" rating for Kangfang Biopharma, projecting revenue growth from 34.19 billion to 85.77 billion CNY from 2025 to 2027, supported by strong commercialization and clear overseas clinical data [1] Group 1: Financial Performance - In H1 2025, Kangfang Biopharma achieved revenue of 14.12 billion CNY, a year-on-year increase of 37.75%, with product sales revenue reaching 14.01 billion CNY, up 49.20% [2] - R&D expenses were 7.31 billion CNY, increasing by 23.06%, while sales and management expenses rose by 29.84% and 34.00%, respectively [1] Group 2: Product Development and Clinical Trials - The commercialization of core dual antibodies, Kadunil and Ivosidenib, is driving revenue growth, with expectations for further performance increases as new products and indications are approved [2] - Ivosidenib's OS data presented at the WCLC 2025 showed significant improvement, with an OSHR of 0.70 in the North American population, indicating a strong survival benefit [2][3] - Ongoing clinical trials for Ivosidenib include various cancer types, with a focus on expanding indications, which could enhance its market potential [3]

Core Viewpoint - The report maintains a "buy" rating for Kangfang Biopharma (09926), projecting significant revenue growth from 2025 to 2027, driven by strong commercialization and a promising innovation pipeline [1][2]. Group 1: Financial Performance - Kangfang Biopharma reported a revenue of 14.12 billion yuan for H1 2025, representing a year-on-year increase of 37.75% [1][2]. - The sales revenue from product sales reached 14.01 billion yuan, reflecting a 49.20% year-on-year growth [2]. - R&D expenses were 7.31 billion yuan, up 23.06% year-on-year, while sales and management expenses increased by 29.84% and 34.00%, respectively [1]. Group 2: Product Development and Clinical Trials - The commercialization of core dual antibodies, Kadunil and Ivosidenib, is driving revenue growth, with expectations for further performance improvements as new products and indications are approved [2]. - The WCLC 2025 conference showcased updated overall survival (OS) data for Ivosidenib, indicating a significant improvement in survival benefits, particularly in the North American population [2][3]. - Ongoing clinical trials for Ivosidenib include various cancer types, with a focus on expanding its indications, which could enhance its market potential [3].

Core Insights - The Hong Kong Technology ETF (513560) has seen a significant increase, with a nearly 2% jump on September 11, 2025, marking its fourth consecutive rise and reaching a new high since its inception [1] - The ETF has achieved an impressive 88.27% net value increase over the past year, ranking first among comparable funds [2] - The underlying index, the CSI Hong Kong Stock Connect Technology Index, consists of 50 large-cap technology companies with high R&D investment and revenue growth, reflecting the overall performance of technology leaders in the Hong Kong Stock Connect [2][5] Performance Comparison - The CSI Hong Kong Stock Connect Technology Index has outperformed other indices, with a cumulative increase of 60.63% from 2018 to September 11, 2025, compared to 6.11% for the Hang Seng Technology Index and 0.56% for the Hong Kong Stock Connect Internet Index [2][3] - Over the past year, the CSI Hong Kong Stock Connect Technology Index has increased by 90.96%, while the Hang Seng Technology Index rose by 70.64% [3] Fund Details - As of September 11, 2025, the Hong Kong Technology ETF has reached a size of 770 million yuan, with 520 million shares outstanding, both marking new highs since its establishment [5] - The ETF has seen a net inflow of 8.89 million yuan recently, with a total of 58.60 million yuan net inflow over the past five trading days [5] Market Trends - The U.S. investors' interest in the Chinese market has reached its highest level since 2021, particularly in areas like humanoid robots, biotechnology, and drug development [4] - The Hong Kong internet sector is highlighted for its potential due to self-developed AI chips and cloud business expansion, alongside attractive valuations and improving asset quality [4]